Literature DB >> 20441792

Ablation of LKB1 in the heart leads to energy deprivation and impaired cardiac function.

Niels Jessen1, Ho-Jin Koh, Clifford D Folmes, Cory Wagg, Nobuharu Fujii, Bo Løfgren, Cordula M Wolf, Charles I Berul, Michael F Hirshman, Gary D Lopaschuk, Laurie J Goodyear.   

Abstract

Energy deprivation in the myocardium is associated with impaired heart function and increased morbidity. LKB1 is a kinase that is required for activation of AMP-activated protein kinase (AMPK) as well as 13 AMPK-related protein kinases. AMPK stimulates ATP production during ischemia and prevents post-ischemic dysfunction. We used the Cre-Lox system to generate mice where LKB1 was selectively knocked out in cardiomyocytes and muscle cells (LKB1-KO) to assess the role of LKB1 on cardiac function in these mice. Heart rates of LKB1-KO mice were reduced and ventricle diameter was increased. Ex vivo, cardiac function was impaired during aerobic perfusion of isolated working hearts, and recovery of function after ischemia was reduced. Although oxidative metabolism and mitochondrial function were normal, the AMP/ATP ratio was increased in LKB1-KO hearts. This was associated with a complete ablation of AMPKalpha2 activity, and a stimulation of signaling through the mammalian target of rapamycin. Our results establish a critical role for LKB1 for normal cardiac function under both aerobic conditions and during recovery after ischemia. Ablation of LKB1 leads to a decreased cardiac efficiency despite normal mitochondrial oxidative metabolism. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20441792      PMCID: PMC2893233          DOI: 10.1016/j.bbadis.2010.04.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  33 in total

Review 1.  Myocardial substrate metabolism in the normal and failing heart.

Authors:  William C Stanley; Fabio A Recchia; Gary D Lopaschuk
Journal:  Physiol Rev       Date:  2005-07       Impact factor: 37.312

2.  Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3.

Authors:  Ho-Jin Koh; David E Arnolds; Nobuharu Fujii; Thien T Tran; Marc J Rogers; Niels Jessen; Yangfeng Li; Chong Wee Liew; Richard C Ho; Michael F Hirshman; Rohit N Kulkarni; C Ronald Kahn; Laurie J Goodyear
Journal:  Mol Cell Biol       Date:  2006-09-11       Impact factor: 4.272

3.  The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.

Authors:  Reuben J Shaw; Katja A Lamia; Debbie Vasquez; Seung-Hoi Koo; Nabeel Bardeesy; Ronald A Depinho; Marc Montminy; Lewis C Cantley
Journal:  Science       Date:  2005-11-24       Impact factor: 47.728

4.  AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise.

Authors:  N Musi; N Fujii; M F Hirshman; I Ekberg; S Fröberg; O Ljungqvist; A Thorell; L J Goodyear
Journal:  Diabetes       Date:  2001-05       Impact factor: 9.461

Review 5.  Protein turnover in cardiac cell growth and survival.

Authors:  Nadia Hedhli; Michel Pelat; Christophe Depre
Journal:  Cardiovasc Res       Date:  2005-08-02       Impact factor: 10.787

6.  TSC2 mediates cellular energy response to control cell growth and survival.

Authors:  Ken Inoki; Tianqing Zhu; Kun-Liang Guan
Journal:  Cell       Date:  2003-11-26       Impact factor: 41.582

7.  LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1.

Authors:  Jose M Lizcano; Olga Göransson; Rachel Toth; Maria Deak; Nick A Morrice; Jérôme Boudeau; Simon A Hawley; Lina Udd; Tomi P Mäkelä; D Grahame Hardie; Dario R Alessi
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

8.  Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase.

Authors:  Yanqiu Xing; Nicolas Musi; Nobuharu Fujii; Liqun Zou; Ivan Luptak; Michael F Hirshman; Laurie J Goodyear; Rong Tian
Journal:  J Biol Chem       Date:  2003-05-23       Impact factor: 5.157

9.  Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction.

Authors:  Kei Sakamoto; Afshan McCarthy; Darrin Smith; Kevin A Green; D Grahame Hardie; Alan Ashworth; Dario R Alessi
Journal:  EMBO J       Date:  2005-05-05       Impact factor: 11.598

10.  Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1.

Authors:  Kei Sakamoto; Elham Zarrinpashneh; Grant R Budas; Anne-Catherine Pouleur; Anindya Dutta; Alan R Prescott; Jean-Louis Vanoverschelde; Alan Ashworth; Aleksandar Jovanović; Dario R Alessi; Luc Bertrand
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-12-06       Impact factor: 4.310

View more
  26 in total

1.  Mitochondrial and performance adaptations to exercise training in mice lacking skeletal muscle LKB1.

Authors:  Colby B Tanner; Steven R Madsen; David M Hallowell; Darren M J Goring; Timothy M Moore; Shalene E Hardman; Megan R Heninger; Daniel R Atwood; David M Thomson
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-08-27       Impact factor: 4.310

Review 2.  Programming apoptosis and autophagy with novel approaches for diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2015       Impact factor: 1.990

Review 3.  Erythropoietin and diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  World J Diabetes       Date:  2015-10-25

4.  mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  World J Diabetes       Date:  2015-03-15

5.  LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation.

Authors:  Grace E Kim; Jenna L Ross; Chaoqin Xie; Kevin N Su; Vlad G Zaha; Xiaohong Wu; Monica Palmeri; Mohammed Ashraf; Joseph G Akar; Kerry S Russell; Fadi G Akar; Lawrence H Young
Journal:  Cardiovasc Res       Date:  2015-10-01       Impact factor: 10.787

6.  Inactivation of MARK4, an AMP-activated protein kinase (AMPK)-related kinase, leads to insulin hypersensitivity and resistance to diet-induced obesity.

Authors:  Chao Sun; Liang Tian; Jia Nie; Hai Zhang; Xiao Han; Yuguang Shi
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

Review 7.  Cutting through the complexities of mTOR for the treatment of stroke.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2014-05       Impact factor: 1.990

8.  AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism.

Authors:  Miranda M Sung; Beshay N Zordoky; Adam L Bujak; James S V Lally; David Fung; Martin E Young; Sandrine Horman; Edward J Miller; Peter E Light; Bruce E Kemp; Gregory R Steinberg; Jason R B Dyck
Journal:  Cardiovasc Res       Date:  2015-05-28       Impact factor: 10.787

Review 9.  Taking aim at Alzheimer's disease through the mammalian target of rapamycin.

Authors:  Kenneth Maiese
Journal:  Ann Med       Date:  2014-08-08       Impact factor: 4.709

10.  Detection of differentially methylated gene promoters in failing and nonfailing human left ventricle myocardium using computation analysis.

Authors:  Christopher A Koczor; Eva K Lee; Rebecca A Torres; Amy Boyd; J David Vega; Karan Uppal; Fan Yuan; Earl J Fields; Allen M Samarel; William Lewis
Journal:  Physiol Genomics       Date:  2013-05-21       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.